Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Evaluation of the 3D fractal dimension as a marker of structural brain complexity in multiple-acquisition MRI.

Krohn S, Froeling M, Leemans A, Ostwald D, Villoslada P, Finke C, Esteban FJ.

Hum Brain Mapp. 2019 May 15. doi: 10.1002/hbm.24599. [Epub ahead of print]

PMID:
31090254
2.

Personalizing medical care for patients with MS: Monitoring brainstem damage by infrared oculography.

Villoslada P, Green AJ, Galetta S.

Neurology. 2019 May 14;92(20):929-930. doi: 10.1212/WNL.0000000000007493. Epub 2019 Apr 19. No abstract available.

PMID:
31004068
3.

MAPK pathway and B cells overactivation in multiple sclerosis revealed by phosphoproteomics and genomic analysis.

Kotelnikova E, Kiani NA, Messinis D, Pertsovskaya I, Pliaka V, Bernardo-Faura M, Rinas M, Vila G, Zubizarreta I, Pulido-Valdeolivas I, Sakellaropoulos T, Faigle W, Silberberg G, Masso M, Stridh P, Behrens J, Olsson T, Martin R, Paul F, Alexopoulos LG, Saez-Rodriguez J, Tegner J, Villoslada P.

Proc Natl Acad Sci U S A. 2019 May 7;116(19):9671-9676. doi: 10.1073/pnas.1818347116. Epub 2019 Apr 19.

PMID:
31004050
4.

Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial.

Zubizarreta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, Saiz A, Llufriu S, Sepulveda M, Sola-Valls N, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Casanova B, Martinez Gines M, Tellez N, Oreja-Guevara C, Español M, Trias E, Cid J, Juan M, Lozano M, Blanco Y, Steinman L, Benitez-Ribas D, Villoslada P.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8463-8470. doi: 10.1073/pnas.1820039116. Epub 2019 Apr 8.

5.

Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.

Nolan-Kenney RC, Liu M, Akhand O, Calabresi PA, Paul F, Petzold A, Balk L, Brandt AU, Martínez-Lapiscina EH, Saidha S, Villoslada P, Al-Hassan AA, Behbehani R, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Papadopoulou A, Pisa M, Zimmermann H, Galetta SL, Balcer LJ; International Multiple Sclerosis Visual System Consortium.

Ann Neurol. 2019 May;85(5):618-629. doi: 10.1002/ana.25462. Epub 2019 Apr 10.

PMID:
30851125
6.

Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation.

Villoslada P, Vila G, Colafrancesco V, Moreno B, Fernandez-Diez B, Vazquez R, Pertsovskaya I, Zubizarreta I, Pulido-Valdeolivas I, Messeguer J, Vendrell-Navarro G, Frade JM, López-Sánchez N, Teixido M, Giralt E, Masso M, Dugas JC, Leonoudakis D, Lariosa-Willingham KD, Steinman L, Messeguer A.

Neurotherapeutics. 2019 Feb 27. doi: 10.1007/s13311-019-00717-4. [Epub ahead of print]

PMID:
30815844
7.

Remyelination: a good neuroprotective strategy for preventing axonal degeneration?

Villoslada P, Martinez-Lapiscina EH.

Brain. 2019 Feb 1;142(2):233-236. doi: 10.1093/brain/awy349. No abstract available.

PMID:
30698759
8.

Author Correction: Subgenual anterior cingulate cortex controls sadness-induced modulations of cognitive and emotional network hubs.

Ramirez-Mahaluf JP, Perramon J, Otal B, Villoslada P, Compte A.

Sci Rep. 2018 Jul 20;8(1):11237. doi: 10.1038/s41598-018-29005-5.

9.

Combined walking outcome measures identify clinically meaningful response to prolonged-release fampridine.

Sola-Valls N, Blanco Y, Sepúlveda M, Llufriu S, Martínez-Lapiscina EH, Zubizarreta I, Pulido-Valdeolivas I, Montejo C, Villoslada P, Saiz A.

Ther Adv Neurol Disord. 2018 Jun 10;11:1756286418780007. doi: 10.1177/1756286418780007. eCollection 2018.

10.

Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis.

Andorra M, Nakamura K, Lampert EJ, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Martinez-Heras E, Sola-Valls N, Sepulveda M, Tercero-Uribe A, Blanco Y, Saiz A, Villoslada P, Martinez-Lapiscina EH.

JAMA Neurol. 2018 Oct 1;75(10):1246-1255. doi: 10.1001/jamaneurol.2018.1596.

PMID:
29971335
11.

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.

Flórez-Grau G, Zubizarreta I, Cabezón R, Villoslada P, Benitez-Ribas D.

Front Immunol. 2018 May 31;9:1169. doi: 10.3389/fimmu.2018.01169. eCollection 2018. Review.

12.

Subgenual anterior cingulate cortex controls sadness-induced modulations of cognitive and emotional network hubs.

Ramirez-Mahaluf JP, Perramon J, Otal B, Villoslada P, Compte A.

Sci Rep. 2018 Jun 4;8(1):8566. doi: 10.1038/s41598-018-26317-4. Erratum in: Sci Rep. 2018 Jul 20;8(1):11237.

13.

Predictors of vision impairment in Multiple Sclerosis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Pulido-Valdeolivas I, Zubizarreta I, Llufriu S, Blanco Y, Sola-Valls N, Sepulveda M, Guerrero A, Alba S, Andorra M, Camos A, Sanchez-Vela L, Alfonso V, Saiz A, Villoslada P.

PLoS One. 2018 Apr 17;13(4):e0195856. doi: 10.1371/journal.pone.0195856. eCollection 2018.

14.

Identification and treatment of the visual processing asymmetry in MS patients with optic neuritis: The Pulfrich phenomenon.

Sobhanian MJ, Agarwal R, Meltzer E, Kildebeck E, Frohman BS, Frohman AN, Galetta SL, Saidha S, White O, Villoslada P, Paul F, Petzold A, Rennaker RL, Martinez-Lapiscina EH, Balcer LJ, Kardon R, Frohman EM, Frohman TC.

J Neurol Sci. 2018 Apr 15;387:60-69. doi: 10.1016/j.jns.2018.01.029. Epub 2018 Feb 3.

PMID:
29571874
15.

Multicenter reliability of semiautomatic retinal layer segmentation using OCT.

Oberwahrenbrock T, Traber GL, Lukas S, Gabilondo I, Nolan R, Songster C, Balk L, Petzold A, Paul F, Villoslada P, Brandt AU, Green AJ, Schippling S.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 13;5(3):e449. doi: 10.1212/NXI.0000000000000449. eCollection 2018 May.

16.

Harnessing electronic medical records to advance research on multiple sclerosis.

Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA.

Mult Scler. 2019 Mar;25(3):408-418. doi: 10.1177/1352458517747407. Epub 2018 Jan 9.

PMID:
29310490
17.

Time is vision: The importance of the early discovery and diagnosis of optic neuritis.

Villoslada P, Martinez-Lapiscina EH.

Mult Scler. 2017 Dec;23(14):1806-1807. doi: 10.1177/1352458517739140. No abstract available.

PMID:
29154727
18.

OCT as a window to the MS brain: The view becomes slightly clearer.

Toosy AT, Naismith RT, Villoslada P.

Neurology. 2017 Dec 12;89(24):2404-2405. doi: 10.1212/WNL.0000000000004755. Epub 2017 Nov 15. No abstract available.

PMID:
29142085
19.

Dynamics and heterogeneity of brain damage in multiple sclerosis.

Kotelnikova E, Kiani NA, Abad E, Martinez-Lapiscina EH, Andorra M, Zubizarreta I, Pulido-Valdeolivas I, Pertsovskaya I, Alexopoulos LG, Olsson T, Martin R, Paul F, Tegnér J, Garcia-Ojalvo J, Villoslada P.

PLoS Comput Biol. 2017 Oct 26;13(10):e1005757. doi: 10.1371/journal.pcbi.1005757. eCollection 2017 Oct.

20.

Correction to: the disruption of mitochondrial axonal transport is an early event in neuroinflammation.

Errea O, Moreno B, Gonzalez-Franquesa A, Garcia-Roves PM, Villoslada P.

J Neuroinflammation. 2017 Oct 23;14(1):206. doi: 10.1186/s12974-017-0979-2. No abstract available.

21.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
22.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
23.

Burden of neurological diseases in the US revealed by web searches.

Baeza-Yates R, Sangal PM, Villoslada P.

PLoS One. 2017 May 22;12(5):e0178019. doi: 10.1371/journal.pone.0178019. eCollection 2017.

24.

Metabolomic signatures associated with disease severity in multiple sclerosis.

Villoslada P, Alonso C, Agirrezabal I, Kotelnikova E, Zubizarreta I, Pulido-Valdeolivas I, Saiz A, Comabella M, Montalban X, Villar L, Alvarez-Cermeño JC, Fernández O, Alvarez-Lafuente R, Arroyo R, Castro A.

Neurol Neuroimmunol Neuroinflamm. 2017 Jan 27;4(2):e321. doi: 10.1212/NXI.0000000000000321. eCollection 2017 Mar.

25.

Structural networks involved in attention and executive functions in multiple sclerosis.

Llufriu S, Martinez-Heras E, Solana E, Sola-Valls N, Sepulveda M, Blanco Y, Martinez-Lapiscina EH, Andorra M, Villoslada P, Prats-Galino A, Saiz A.

Neuroimage Clin. 2016 Dec 5;13:288-296. doi: 10.1016/j.nicl.2016.11.026. eCollection 2017.

26.

Epicenters of dynamic connectivity in the adaptation of the ventral visual system.

Prčkovska V, Huijbers W, Schultz A, Ortiz-Teran L, Peña-Gomez C, Villoslada P, Johnson K, Sperling R, Sepulcre J.

Hum Brain Mapp. 2017 Apr;38(4):1965-1976. doi: 10.1002/hbm.23497. Epub 2016 Dec 28.

27.

First-in-class inhibitor of the T cell receptor for the treatment of autoimmune diseases.

Borroto A, Reyes-Garau D, Jiménez MA, Carrasco E, Moreno B, Martínez-Pasamar S, Cortés JR, Perona A, Abia D, Blanco S, Fuentes M, Arellano I, Lobo J, Heidarieh H, Rueda J, Esteve P, Cibrián D, Martinez-Riaño A, Mendoza P, Prieto C, Calleja E, Oeste CL, Orfao A, Fresno M, Sánchez-Madrid F, Alcamí A, Bovolenta P, Martín P, Villoslada P, Morreale A, Messeguer A, Alarcon B.

Sci Transl Med. 2016 Dec 21;8(370):370ra184. doi: 10.1126/scitranslmed.aaf2140.

PMID:
28003549
28.

Impairment of decision-making in multiple sclerosis: A neuroeconomic approach.

Sepúlveda M, Fernández-Diez B, Martínez-Lapiscina EH, Llufriu S, Sola-Valls N, Zubizarreta I, Blanco Y, Saiz A, Levy D, Glimcher P, Villoslada P.

Mult Scler. 2017 Nov;23(13):1762-1771. doi: 10.1177/1352458516682103. Epub 2016 Dec 7.

29.

Erratum to: Making sense of big data in health research: towards an EU action plan.

Auffray C, Balling R, Barroso I, Bencze L, Benson M, Bergeron J, Bernal-Delgado E, Blomberg N, Bock C, Conesa A, Del Signore S, Delogne C, Devilee P, Di Meglio A, Eijkemans M, Flicek P, Graf N, Grimm V, Guchelaar HJ, Guo YK, Gut IG, Hanbury A, Hanif S, Hilgers RD, Honrado Á, Hose DR, Houwing-Duistermaat J, Hubbard T, Janacek SH, Karanikas H, Kievits T, Kohler M, Kremer A, Lanfear J, Lengauer T, Maes E, Meert T, Müller W, Nickel D, Oledzki P, Pedersen B, Petkovic M, Pliakos K, Rattray M, I Màs JR, Schneider R, Sengstag T, Serra-Picamal X, Spek W, Vaas LA, van Batenburg O, Vandelaer M, Varnai P, Villoslada P, Vizcaíno JA, Wubbe JP, Zanetti G.

Genome Med. 2016 Nov 7;8(1):118. No abstract available.

30.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

31.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

32.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

33.

Phenytoin for neuroprotection.

Martinez-Lapiscina EH, Andorra M, Sanchez-Dalmau B, Villoslada P.

Lancet Neurol. 2016 Aug;15(9):901-902. doi: 10.1016/S1474-4422(16)30093-X. No abstract available.

PMID:
27478946
34.

Making sense of big data in health research: Towards an EU action plan.

Auffray C, Balling R, Barroso I, Bencze L, Benson M, Bergeron J, Bernal-Delgado E, Blomberg N, Bock C, Conesa A, Del Signore S, Delogne C, Devilee P, Di Meglio A, Eijkemans M, Flicek P, Graf N, Grimm V, Guchelaar HJ, Guo YK, Gut IG, Hanbury A, Hanif S, Hilgers RD, Honrado Á, Hose DR, Houwing-Duistermaat J, Hubbard T, Janacek SH, Karanikas H, Kievits T, Kohler M, Kremer A, Lanfear J, Lengauer T, Maes E, Meert T, Müller W, Nickel D, Oledzki P, Pedersen B, Petkovic M, Pliakos K, Rattray M, I Màs JR, Schneider R, Sengstag T, Serra-Picamal X, Spek W, Vaas LA, van Batenburg O, Vandelaer M, Varnai P, Villoslada P, Vizcaíno JA, Wubbe JP, Zanetti G.

Genome Med. 2016 Jun 23;8(1):71. doi: 10.1186/s13073-016-0323-y. Erratum in: Genome Med. 2016 Nov 7;8(1):118.

35.

The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.

Cruz-Herranz A, Balk LJ, Oberwahrenbrock T, Saidha S, Martinez-Lapiscina EH, Lagreze WA, Schuman JS, Villoslada P, Calabresi P, Balcer L, Petzold A, Green AJ, Paul F, Brandt AU, Albrecht P; IMSVISUAL consortium.

Neurology. 2016 Jun 14;86(24):2303-9. doi: 10.1212/WNL.0000000000002774. Epub 2016 May 25.

36.

Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A.

Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun.

37.

Power estimation for non-standardized multisite studies.

Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F; International Multiple Sclerosis Genetics Consortium. Electronic address: AIVINSON@PARTNERS.ORG, Hauser SL, Oksenberg JR, Henry RG.

Neuroimage. 2016 Jul 1;134:281-294. doi: 10.1016/j.neuroimage.2016.03.051. Epub 2016 Apr 1.

38.

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study.

Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium.

Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.

PMID:
27011339
39.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
40.

Reproducibility of the Structural Connectome Reconstruction across Diffusion Methods.

Prčkovska V, Rodrigues P, Puigdellivol Sanchez A, Ramos M, Andorra M, Martinez-Heras E, Falcon C, Prats-Galino A, Villoslada P.

J Neuroimaging. 2016 Jan-Feb;26(1):46-57. doi: 10.1111/jon.12298. Epub 2015 Oct 14.

PMID:
26464179
41.

Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

Villoslada P, Rovira A, Montalban X, Arroyo R, Paul F, Meca-Lallana V, Ramo C, Fernandez O, Saiz A, Garcia-Merino A, Ramió-Torrentà L, Casanova B, Oreja-Guevara C, Muñoz D, Martinez-Rodriguez JE, Lensch E, Prieto JM, Meuth SG, Nuñez X, Campás C, Pugliese M; NeuroAdvan study.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 10;2(5):e147. doi: 10.1212/NXI.0000000000000147. eCollection 2015 Oct.

42.

Improved Framework for Tractography Reconstruction of the Optic Radiation.

Martínez-Heras E, Varriano F, Prčkovska V, Laredo C, Andorrà M, Martínez-Lapiscina EH, Calvo A, Lampert E, Villoslada P, Saiz A, Prats-Galino A, Llufriu S.

PLoS One. 2015 Sep 16;10(9):e0137064. doi: 10.1371/journal.pone.0137064. eCollection 2015.

43.

Pituitary-ovary axis and ovarian reserve in fertile women with multiple sclerosis: A pilot study.

Sepúlveda M, Ros C, Martínez-Lapiscina EH, Solà-Valls N, Hervàs M, Llufriu S, La Puma D, Casals E, Blanco Y, Villoslada P, Graus F, Castelo-Branco C, Saiz A.

Mult Scler. 2016 Apr;22(4):564-8. doi: 10.1177/1352458515602339. Epub 2015 Sep 11.

PMID:
26362892
44.

The analysis of semantic networks in multiple sclerosis identifies preferential damage of long-range connectivity.

Abad E, Sepulcre J, Martinez-Lapiscina EH, Zubizarreta I, Garcia-Ojalvo J, Villoslada P.

Mult Scler Relat Disord. 2015 Sep;4(5):387-394. doi: 10.1016/j.msard.2015.07.002. Epub 2015 Jul 8.

PMID:
26346784
45.

The disruption of mitochondrial axonal transport is an early event in neuroinflammation.

Errea O, Moreno B, Gonzalez-Franquesa A, Garcia-Roves PM, Villoslada P.

J Neuroinflammation. 2015 Aug 28;12:152. doi: 10.1186/s12974-015-0375-8. Erratum in: J Neuroinflammation. 2017 Oct 23;14(1):206.

46.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
47.

Acute optic neuritis: Unmet clinical needs and model for new therapies.

Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, Cadavid D, Balcer LJ.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135. doi: 10.1212/NXI.0000000000000135. eCollection 2015 Aug. Review.

48.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

49.

A Population Approach to Characterize Interferon Beta-1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis.

Gulati A, Bagnato F, Villoslada P, Velez de Mendizabal N.

CPT Pharmacometrics Syst Pharmacol. 2015 May;4(5):295-304. doi: 10.1002/psp4.36. Epub 2015 Apr 24.

50.

Changes in macular layers in the early course of non-arteritic ischaemic optic neuropathy.

Keller J, Oakley JD, Russakoff DB, Andorrà-Inglés M, Villoslada P, Sánchez-Dalmau BF.

Graefes Arch Clin Exp Ophthalmol. 2016 Mar;254(3):561-7. doi: 10.1007/s00417-015-3066-3. Epub 2015 May 28.

PMID:
26016810

Supplemental Content

Loading ...
Support Center